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BakZinc-binding protein-89 regulates Bak to facilitate apoptosis in cancer cells. This study examined if zinc-binding
protein-89 regulates Bak through an epigenetic mechanism in hepatocellular carcinoma. We ﬁrst demonstrated
that the expression of Bak was reduced but the levels of deoxyribonucleic acid methyltransferase 1 and histone
deacetylase 3 were increased in hepatocellular carcinoma cancer tissues compared to the corresponding
non-cancer tissues. Moreover, there was a negative correlation between Bak expression and
deoxyribonucleic acid methyltransferase 1 levels in hepatocellular carcinoma. Administration of zinc-binding
protein-89 downregulated histone deacetylase 3 expression and suppressed the activities of histone deacetylase
and deoxyribonucleic acid methyltransferase, which led to maintenance of histone acetylation status, inhibited
the binding of methyl-CpG-binding protein 2 to genomic deoxyribonucleic acid and demethylated CpG islands
in the Bak promoter in hepatocellular carcinoma cells. Using the xenograft mouse tumormodel, we demonstrat-
ed that zinc-binding protein-89 or inhibitors of either epigenetic enzymes could stimulate Bak expression, in-
duce apoptosis, and arrest tumor growth and that the maximal effort was achieved when zinc-binding
protein-89 and the enzyme inhibitors were used in combination. Conclusively, zinc-binding protein-89
upregulates the expression of Bak by targetingmultiple components of the epigenetic pathway in hepatocellular
carcinoma.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
ZBP-89, a Kruppel-type zinc-ﬁnger transcription factor, binds to
gene promoter GC-rich sequence to activate or suppress gene tran-
scription which is closely related to cell growth and cell death [1,2].
Previously, we reported that ZBP-89 induced Bak gene expression,
a pro-apoptotic protein known to stimulate apoptosis in hepatocel-
lular carcinoma (HCC) cells [3]. In addition to its ability to bind to
gene promoters, ZBP-89 also forms protein–protein interactions2.
For example, ZBP-89 interacts with histone deacetylases (HDAC) to
repress p16 and vimentin gene transcription [2,4], or interacts with
p53, GATA-1 and/or FOG-1 to activate gene expression [5,6]. TheseP, chromatin immunoprecipita-
transferase; HCC, hepatocellular
G-binding protein 2; MIHA, im-
, sodium valproic acid; Zebu,
ce ofWales Hospital, Shatin, NT,
ights reserved.studies propose a link between ZBP-89 and epigenetic regulation,
though the detailed mechanism is not understood. Bak promoter
methylation was reported previously [7,8]. Therefore we queried
whether the regulation of Bak expression by ZBP-89 is subjected to
epigenetic regulation.
HDAC and DNA methyltransferase (DNMT) inhibitors can synergi-
cally regulate the same genomic targets [9]. They may synergize when
added together, although they activate different gene targets through
different mechanisms [6]. An increase in the acetylated histone H3
and histone H4 is closely correlated with gene expression [10]. HDAC3
is regarded as a biomarker of HCC recurrence and therapy target
[11,12]. The roles of HDAC and DNMT in the regulation of Bak are
known.
CpG dinucleotide islands are usually located in the promoter region
of given genes. At these locations, CG dinucleotides that become meth-
ylated suppress gene expression. DNA methylation may silence gene
expression through either interfering with transcription factor binding
or recruiting methylated DNA binding proteins [13,14]. Aberrant
genome-wide DNA methylation mediated by DNMT has been thought
to be related to tumorigenesis. Increased expression of DNMT in HCC
is correlated with poor prognosis and survival [15,16].
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ZBP-89 induced Bak gene expression [3]. The aim of this study was to
determine whether ZBP-89 regulated Bak gene expression through its
ability to modulate HDAC and DNMT.
2. Materials and methods
2.1. Chemicals and reagents
Antibodies against ZBP-89, PARP, methyl-CpG-binding protein 2
(MeCP2); protein A/G PLUS-agarose beads, ZBP-89 siRNA, HDAC3
siRNA and DNMT1 siRNAwere obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). HDAC3, HDAC4, DNMT1 and DNMT3a, DNMT3b anti-
bodies were provided by Cayman Chemicals (Ann Arbor, MI). All other
chemicals and reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise speciﬁed.
2.2. HCC patient samples, cell lines, siRNA transfection, and adenovirus in-
fection of cells
103 HCC tissue samples and thematched non-cancerous liver tissue
samples were obtained from patients with HCC, who underwent surgi-
cal resection and the detailed information of these samples was shown
in Table S1. The studywas approved by the local Clinical Research Ethics
Committee. HCC cells, PLC/PRF/5 and HepG2 cells were purchased from
ATCC. HepG2 cells are low tumorigenic cells but they are positive for
HBV antigens. PLC/PRF/5 cells positive forHBV showhigher tumorigenic
ability. MIHA cells are a SV40-immortalized normal liver cell line. 10 μM
of each ZBP-89 siRNA, HDAC3 siRNA, or DNMT1 siRNAwere transfected
into the cells with FuGENE reagent (Roche, Indianapolis, IN). The
replication-deﬁcient recombinant adenoviral expression vector Ad-
ZBP-89 was used according to previous publications [3,5].
2.3. Activities of HDAC and DNMT
The effect of ZBP-89 onHDAC activity in cancer cells was assessed by
the Fluor de Lys-Green HDAC Assay Kit (Enzo Life Science, Farmingdale,
NY). The experiment was performed according to the manufacturer's
protocol. DNMT was prepared according to a previous publication
[17]. The S-adenosyl-L-methionine was used as the methyl group
donor. The activity of DNMT was detected by the methyltransferase ac-
tivity kit (Enzo Life Science, Farmingdale, NY).
2.4. Co-immunoprecipitation (Co-IP) and Western blotting
These experimentswere performed according to the previous publi-
cations [3,5]. Brieﬂy, cell lysateswere incubated overnight with primary
antibody after being precleared with protein A/G PLUS-agarose beads.
Immunocomplexes were precipitated after incubating with protein
A/G PLUS-agarose beads. Immunocomplexes were released by boil-
ing in 2 × SDS sample buffer for Western blot analysis. The positive
signals were visualized by ECL reagent kit (GE Healthcare).
2.5. Immunohistochemistry and immunoﬂuorescence
The immunohistochemical examination was carried out according
to our previous publication [3,5]. Brieﬂy, the tissue sections were incu-
batedwith a primary antibody followed by aHRP-labeled IgG secondary
antibody. The antigen–antibody complex was visualized by the
diaminobenzidine method. Phosphate-buffered saline was used as a
negative control instead of the primary antibody. For immunoﬂuores-
cent staining, after the cells were ﬁxed with 4% paraformaldehyde,
they were incubated with primary antibody, followed by a FITC- or
rhodamine-labeled secondary antibody. Fluorescent cells were visual-
ized using the Zeiss Axioplan 2 microscope (Zeiss, Germany).2.6. Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed based on
the protocol previously published with some modiﬁcations [18]. The
following primers were used to detect precipitated sequence:
S1_F1: GGGAGGATGGGAGGTTGGGGG;
S1_R1: AGCCCCTGCCCTCAGGGTTC;
S2_F2: GAGGTGGGGGAGAAGATCAAAGACA;
S2_R2: CGGCACCCGGCTCCAATCAG.
2.7. Sodium bisulﬁte modiﬁcation sequencing of Bak promoter
Sodium bisulﬁte modiﬁed sequencing was carried out using the
377DNA sequencer (ABI) and gene promoter primers were designed
using MSP primer. Totally, 1 μg of genomic DNA was modiﬁed and
cleared up by EZ DNA modiﬁcation-Gold kit (Zymo Research, Irvine,
CA). The following Bak gene promoter primers were used:
msp_F1: GTTTAGGTTGGAGTGTAGTGGGTTA,
msp_R1: CCAAAATTATACCACTACACTCCTACC,
msp_F2: GTGGTTATAGAGTAATTTTTTTTAGAGGGA,
msp_R2: ACCTACCCAAAAAAACCTTAAACTT.
2.8. Cell proliferation and apoptosis detection
Cell proliferation was determined by MTT assay as described previ-
ously [3,5]. Apoptosis was determined by the Vybrant® Apoptosis
Assay Kit (Invitrogen, Carlsbad, CA) and performed according to the in-
troduction of the manufacture [3,5].
2.9. Xenograft animal model
The xenograft tumormodel was generated by injecting 2 × 106 PLC/
PRF/5 cells into the left axilla of nudemice and left to grow for 3 weeks.
The control group received 0.9% saline i.p. The Ad-ZBP-89 recombinant
adenoviral vector (1 × 1010 pfu) was administrated by direct injection
into tumor tissues. The ﬁrst injection was done at the beginning of the
implantation, and the second at 7 days later. Valproic acid (VPA) and/
or zebularine (Zebu) was i.p. injected into mice at 50 mg/kg/d and
100 mg/kg/d, respectively, for 7 days [19,20]. At the end of the experi-
ment, the tumor was excised intact and weighted. The expression of
Bak in tumor tissues was determined and apoptosis was analyzed by
TUNEL [21]. The mouse experiment was approved by the local Animal
Research Ethics Committee.
2.10. Statistical analysis
Analyseswere performed using SPSS (SPSS Inc., Chicago, IL). Statisti-
cal analysis was performed by paired t-test, Mann–Whitney U test or
one-way ANOVA. P values of less than 0.05were considered statistically
signiﬁcant. Results were representative of triplicate experiments and
expressed as mean ± SD.
3. Results
3.1. ZBP-89 formed a complex with DNMT1 and HDAC3
There are a number of epigenetic enzymes which are closely associ-
atedwith hepato-carcinogenesis, includingDNMT1, DNMT3a, DNMT3b,
HDAC1, HDAC3 andHDAC4. Therefore, we examined if ZBP-89 could in-
teractwith these epigenetic enzymes. Co-IP studies showed that ZBP-89
protein interacted with DNMT1 and HDAC3 but not the rest, ZBP-89
formed a complex with DNMT1 and HDAC3 that could be detected by
ZBP-89 antibody as well as DNMT1/HDAC3 antibody (Figs. 1A, B and
C). The confocal images showed that ZBP-89 and DNMT1 co-localized
Fig. 1. ZBP-89 interacts with HDAC3 and DNMT1 to form a complex. ZBP-89 bounds HDAC3 and DNMT1 to form a complex in MIHA and PLC/PRF/5 cells (A). The complex could be pre-
cipitated by either HDAC3 antibody or DNMT1 antibody (B, C). Original andmerged confocal images showed that the complex formed by ZBP-89 andDNMT1was primarily located in the
nucleus (D, E). However, in the presence of TSA, a HDAC inhibitor, ZBP-89, was mainly found in the cytoplasm, and some DNMT1 was also present in the cytoplasm. “+” represents pre-
cipitation with labeled antibodies listed in the left side; “−”represents precipitation with control isotype IgG rather than the main antibodies.
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inhibitor TSA, ZBP-89 appeared tomigrate from the nucleus to the cyto-
plasm. Some DNMT1 proteins co-migrated with ZBP-89 to the cyto-
plasm, while some DNMT1 proteins remained in the nucleus.3.2. Expression of Bak, DNMT1 and HDAC3 in HCC tissues
In order to elucidate the relationship between Bak, ZBP-89, and two
chromatin-modifying enzymes, Western blot was performed on 103
liver cancer tissues and their non-cancer liver tissues (Fig. 2A). We
found that the levels of Bak, ZBP-89, DNMT1 and HDAC3 were signiﬁ-
cantly different between cancer tissues and paired non-cancer tissues
(P b 0.05, Figs. 2B, C, D and E). The levels of DNMT1 andHDAC3 proteins
were much higher in the cancer tissues than the non-cancer tissues,
whereas Bak expression was lower in the cancer tissues than in theFig. 2. Bak expression is strongly related to ZBP-89, DNMT1 and HDAC3 in HCC. The expression
The grayscale density of proteins bands was shown in a bar chart, according to different HCC di
between cancer tissues and their paired non-cancer tissues (B, C, D and E).non-cancer tissues. Furthermore, immunohistochemical staining con-
ﬁrmed that a lower level of ZBP-89, but a higher level of DNMT1 was
found in poorly-differentiated HCC (Fig. S1).3.3. Inhibition of HDAC and DNMT induced Bak expression and apoptosis
The results showed that VPA and Zebu inhibited the cell proliferation
in a time- and dose- dependent manner (Figs. 3A, B and C). Similar re-
sults were also obtained when the cells were treated with TSA and 5-
aza-dC (data not shown). VPA and Zebu in combination showed the
greatest suppression on cell proliferation, compared with either agent
alone (P b 0.05). Furthermore, both VPA and Zebu induced Bak expres-
sion, and activated PARP cleavage-mediated apoptosis in PLC/PRF/5 and
HepG2 cells (Fig. 3D, Fig. S2). Both agents also enhanced the acetylation
of H4Lys12. These data suggest that Bak expression is regulated byof Bak, ZBP-89, DNMT1 and HDAC3 in different differentiated HCC samples was examined.
fferentiation subtypes. Bak, ZBP-89, DNMT1 and HDAC3 levels were signiﬁcantly different
Fig. 3. HDAC and DNMT inhibitors and ZBP-89 induce Bak expression. VPA and Zebu inhibited the proliferation of PLC/PRF/5, HepG2 and MIHA cells. Combination of VPA and Zebu sig-
niﬁcantly suppressed cells proliferation (A, B and C). Data were shown as mean ± SD. Both VPA acid and Zebu induced Bak expression and cleaved PARP. Treatment of VPA and Zebu
increased histone H4 acetylation (D). Ad5-ZBP-89-mediated ZBP-89 overexpression up-regulated Bak expression in a dose-dependent manner after 24 h infection (E). *, Zebu + VPA
vs VPA, P b 0.05;△,Zebu + VPA vs Zebu, P b 0.05; #, Zebu vs VPA, P b 0.05, one-way ANOVA analysis.
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dition, ectopic expression of ZBP-89 clearly induced expression of the
pro-apoptotic protein Bak (Fig. 3E).
3.4. ZBP-89 inhibited HDAC activity
Both TSA and VPA signiﬁcantly suppressed the activity of HDAC in
both nuclear and cytosol extracts in vitro (P b 0.001, Figs. 4A and B).
Surprisingly, ZBP-89 overexpression also inhibited HDAC activity
(P b 0.05). Furthermore, Western blot analysis showed that ZBP-89
could maintain acetylation at histones H3 lysine 9/14 and H4 lysine 12
(Fig. 4C, lanes 2 and 3, Fig. S3).
3.5. ZBP-89 suppressed DNMT activity and demethylatedmethyl-CpG islands
The overexpression of ZBP-89 signiﬁcantly inhibited DNMT activity
in the nuclear extract (P b 0.001, Fig. 4D). DNMT1 has been reported
to bind DNA at CpG islands [22]. Thus, the ﬁnding suggests that ZBP-
89 might interfere with the promoter CpG methylation by decreasing
DNMT1 activity. Two ZBP-89 DNA binding sites, GGGGGCAGGGG and
GGGAGGTGGGG [23], were identiﬁed (Figs. 5A and B). Chromatin pre-
cipitation method was used to testify the ZBP-89 binding sites. Resultsshowed that 204 bp S1 sequence which is 3 kbp away from exon1,
and 228 bp S2 which is near exon1, were precipitated by ZBP-89 anti-
body and ampliﬁed by primers (Fig. 5C). Furthermore, using Co-IP, we
measured the precipitated MeCP2, a protein that binds to promoter re-
gions [24,25]. The precipitated productswithout proteinase K treatment
were analyzed by SDS-PAGE and Western blotting, and the result
showed that ZBP-89 overexpression inhibited MeCP2 binding to geno-
mic DNA (Fig. 5D). This ﬁnding indicated that ZBP-89 might modulate
Bak expression by decreasing MeCP2 binding to DNA. Using two com-
puter programs (http://www.mspprimer.org/cgi-mspprimer/design.
cgi and http://www.urogene.org/methprimer/index1.html), we found
two potential CpG islands in human Bak promoter (Fig. 5E). Bisulﬁte
modiﬁcation sequencing was performed on these 2 CpG islands and
showed that ZBP-89 could demethylate them (Fig. 5F). In the ﬁrst CpG
island, ZBP-89 demethylated methyl-CpGs, but the second CpG island
was not affected.3.6. Downregulation of HDAC3 and DNMT1 enhanced Bak expression
Although the activities of HDAC3 andDNMT1 are affected by ZBP-89,
it is still unknown if they directly participate in Bak regulation. We
therefore used HDAC3 siRNA and DNMT1 siRNA to knockdown
Fig. 4. ZBP-89 inhibits HDAC and DNMT activities, and increases histone acetylation level. Histone deacetylase activity analysis showed that adenovirus-mediated ZBP-89 overexpression
inhibited HDAC activity in both nuclear and cytosol extracts (A and B). TSA (1 μM) signiﬁcantly suppressed HDAC activity in vitro. Interestingly,Western blot analysis showed that ZBP-89
increased histoneH3 acetylation (Lys9/Lys14) and histone H4 acetylation (Lys12) and decreasedHDAC3 protein level (C, lanes 2 and 3). HDAC3 siRNA upregulated the level of Bak (C, row
1) and increased histoneH3 andH4 acetylation in PLC/PRF/5 andMIHA cells (C, rows 2 and 3). The overexpression of ZBP-89 signiﬁcantly inhibitedDNMT1 activity in nuclear extracts (D).
The activity was also suppressed by DNMT inhibitor Zebu. The downregulation of DNMT1 expression by siRNA increased Bak expression (E, lane 1). ZBP-89 siRNA decreased Bak expres-
sion in both cell lines. Data were shown as mean ± SD in triplicate experiments. *P b 0.05, ***P b 0.001.
2975C.G. Ye et al. / Biochimica et Biophysica Acta 1833 (2013) 2970–2979HDAC3 and DNMT1 respectively. It showed that the downregulation of
HDAC3 and DNMT1 enhanced Bak expression (Figs. 4C and E).
3.7. ZBP-89 enhanced Bak expression, induced apoptosis and inhibited
tumor growth
Thirty nude mice were randomly divided into 5 groups, saline, Ad-
ZBP-89, VPA, Zebu, and VPA plus Zebu. The signiﬁcant inhibition of
tumor growth was observed in mice treated with Ad-ZBP-89, VPA and
Zebu, compared with the saline control (Fig. 6A). The most obviousinhibitionwas observed inmice treatedwith VPA and Zebu in combina-
tion. The expression of Bak was enhanced by ZBP-89, VPA and Zebu and
the TUNEL positive cells were much more in tumor tissues receiving
ZBP-89, VPA and Zebu (Figs. 6B and C).
4. Discussion
The involvement of pro-apoptotic Bak inHCC development, progres-
sion and treatment has been documented. The level of Bak is reduced or
even non-detectable in HCC cells [26,27]. The reduction of Bak
Fig. 5. ZBP-89 demethylates methyl-CpG dinucleotide. Schematic diagram of Bak promoter and ZBP-89 binding sites (A). ChIP experiment showed ZBP-89 binding to two regions. One is
very close to exon1 and the other is 3 kbp away from transcription start site (B). 204 bp S1 sequence which is 3 kbp away from exon1, and 228 bp S2 which is near exon1, were precip-
itated by ZBP-89 antibody and ampliﬁed by primers (C). MeCP2 binds to chromatin in a methylation-dependent manner and is associated with a core repressor complex to silence gene
transcription. Results showed that adenovirus-mediated ZBP-89 overexpression decreasedMeCP2 protein binding to chromatin (D). CpG islands in Bak gene promoter were predicted by
online software and 2 potential CpG islands in Bak promoter were found (E). When ZBP-89 was overexpressed, some methylated CpG regions became demethylated (F).
2976 C.G. Ye et al. / Biochimica et Biophysica Acta 1833 (2013) 2970–2979contributes to the development and progression of HCC [28,29]. The sig-
niﬁcance of Bak inHCC cells is further supported by several experiments
in which different agents induce apoptosis in HCC cells by stimulating
Bak expression [30–33]. Although the signiﬁcance of Bak in HCC has
been reported, the mechanism responsible for its regulation in HCC is
largely unknown. Our previous study has indicated that ZBP-89 may
target a certain region of Bak promoter to induce its expression and sub-
sequently apoptosis [3]. In this studywe further demonstrated that ZBP-
89 stimulated Bak expression through an epigeneticmechanism in HCC.
Sodium butyrate is known to promote ZBP-89-mediated p21waf1
activation in human colorectal cancer cells [34]. ZBP-89 may recruitHDAC1 to the vimentin promoter to repress the expression of vimentin
in human cervical cancer HeLa cells [2]. Furthermore, ZBP-89 and
HDAC3 may form a complex to help HDAC3 bind to the p16 promoter,
resulting in p16 downregulation in human lung cancer cells [4]. To our
best knowledge, there is no report on effect of ZBP-89 on the epigenetic
regulation of Bak. In the present study, we have shown the involvement
of ZBP-89 in the epigenetic regulation of Bak in HCC. First, our Co-IP ex-
periments showed that ZBP-89 protein could form a complex with
DNMT1 and HDAC3, and this ﬁndingwas supported by the confocal ex-
amination showing that ZBP-89 and DNMT1 were co-localized primar-
ily in the nucleus. Interestingly, ZBP-89 along with a portion of DNMT1
Fig. 6. ZBP-89, VPA and Zebu inhibit xenograft tumor growth. The tumor-bearing mice were given saline, Ad-ZBP-89, VPA, Zebu and VPA plus Zebu. Two weeks after the treatment, mice
were sacriﬁced by cervical dislocation. Xenograft tumorswere resected andweighed to determine the growth of tumor (A). The expression of Bakwas examinedby immunohistochemical
staining (B). The apoptosis was analyzed by TUNEL assay (C). *P b 0.05; **P b 0.01. All tests were analyzed using Mann–Whitney U test and compared with saline control group.
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ed with HDAC inhibitor TSA. Second, ZBP-89 could inhibit the activities
of HDAC andDNMT. Itwasnoted that such an inhibitory effect of ZBP-89
onDNMTwas evenmuch greater than the classic DNMT inhibitor, Zebu.
However, the inhibition of HDAC by ZBP-89 wasmuchweaker than the
traditional HDAC inhibitors TSA and VPA. Third, ZBP-89 could maintain
histone H3 lysine 9/14 residues and histone H4 lysine 12 residue acety-
lation status. Fourth, ZBP-89 could signiﬁcantly inhibit the activity of
DNMT that participate in DNA CpG islands de novomethylation. Finally,
ZBP-89 could inhibit MeCP2 binding to genomic DNA and partiallydemethylate Bak promoter CpG islands. These ﬁndings evidently indi-
cate that ZBP-89 is able to target multiple points in the epigenetic path-
way to upregulate the expression of Bak in HCC.
Our study conﬁrms that the level of Bak is reduced in HCC, especially
in thepoorly-differentiatedHCC. However, a gradual decline in Bakwith
a corresponding increase in DNMT1 and HDAC3 was not found to be
correlated with tumor progression from well/moderate differentiated
to poorly differentiated. We do not have a good explanation for this.
But it is possible that there are some unknown relevant co-factors in
poorly differentiated HCC but not in well/moderately differentiated
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to render a signiﬁcant result. Nevertheless, ZBP-89 is able to promote
the expression of Bak inHCC cells. Importantly, we have further demon-
strated that the expression of Bak is controlled by epigenetic elements
in HCC. First, the expression of Bak in liver tissues of HCC is negatively
associated with two important epigenetic enzymes, DNMT1 and
HDAC3, whose levels are increased in the HCC tumor tissues. Second,
the inhibition of either DNMT1 or HDAC3 induces Bak expression and
the maximal inhibition is achieved when both enzymes are simulta-
neously suppressed. These results clearly indicate that both DNMT1
and HDAC3 participate in the expression of Bak in HCC. Third, two
CpG islands were located in the promoter of Bak gene as the result of
our analysis of human Bak gene promoter. Further analysis showed
that the Bak gene is methylated on the dinucleotide CpG islands
found. It is well known that CpG island hypermethylation may inhibit
transcription by interfering with the recruitment and function of basal
transcription factors or transcriptional coactivators [24]. The hyperme-
thylation of CpG islands near the transcriptional regulatory region can
promote the recruitment of themethyl-CpGbindingdomain family pro-
teins includingMeCP2 to facilitate a repressive chromatin environment,
resulting in silencing genes [24]. MeCP2 can also interact with HDAC-
containing complexes to contribute to the histone deacetylation-
mediated transcriptional repression [25]. These concepts are consistent
with our ﬁnding that ZBP-89 inhibits MeCP2 binding to chromatin, and
permits demethylation of the CpG islands within the Bak gene, and sub-
sequently induces Bak expression. Thoughwe do not have data to show
how ZBP-89 inhibits MeCP2 binding to chromatin, it is possible that
ZBP-89may competewithMeCP2 to bind to genomic DNA, and dissoci-
ates MeCP2 from DNA (Fig. S5). Finally, our in vivo experiment demon-
strated that the administration of ZBP-89 signiﬁcantly inhibited the
growth of xenograft HCC tumor and such a tumor-inhibitory effect
was comparable to that of Zebu, a DNMT inhibitor, and VPA, a HDAC in-
hibitor. Importantly, along with the reduction of the tumor size, there
was an increase in Bak expression and occurrence of apoptosis.
In conclusion, we show that the expression of Bak is reduced but the
levels of DNMT1 and HDAC3 are increased in HCC. Bak expression is
negatively associated with levels of these enzymes. ZBP-89 upregulates
Bak expression via decreasing DNMT1 and HDAC3, inhibiting MeCP2
binding to genomic DNA and demethylating CpG islands in the Bak pro-
moter. The application of ZBP-89 enhances Bak expression, induces ap-
optosis and inhibits the growth of HCC tumor in vivo.
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